Trial reportCardiovascular and interventional radiology2019
Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer.
Trial report in Cardiovascular and interventional radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis.European radiology · 2021Pooled it
- Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients.Signal transduction and targeted therapy · 2020Trial
- Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma.Signal transduction and targeted therapy · 2026Article
- Spatial multiomics reveals irreversible electroporation-induced immuno-metabolic characteristics of the inflammatory margin in liver cancer.Communications biology · 2026Article
- Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomaterials research · 2026Review
- Experimental study on synergistic pulses improving the tumor microenvironment and assisting immunotherapy.Frontiers in immunology · 2026Article
- Immunomodulatory impacts of thermal and pulsed field ablation therapy on hepatocellular carcinoma associated with viral hepatitis.Radiologie (Heidelberg, Germany) · 2025Review
- Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity.Bioactive materials · 2025Article
- Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy.Immune network · 2025Review
- Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications.Radiology and oncology · 2025Review
- Percutaneous Image-Guided Ablation of Renal Cancer: Traditional and Emerging Indications, Energy Sources, Techniques, and Future Developments.Medicina (Kaunas, Lithuania) · 2025Review
- Circulating tumor cells in pancreatic cancer: more than liquid biopsy.Therapeutic advances in medical oncology · 2024Review
- Review
- Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy.Biomedicines · 2023Review
- The Important Roles of Natural Killer Cells in Liver Fibrosis.Biomedicines · 2023Review
- Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends.International journal of molecular sciences · 2023Review
- Review
- Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.Frontiers in immunology · 2023Review
- [Irreversible electroporation: present and future in the treatment of hepatocellular carcinoma].Anales del sistema sanitario de Navarra · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThis study aimed to investigate the safety and short-term efficacy of irreversible electroporation (IRE) combined with allogenic natural killer (NK) cell immunotherapy in the treatment of patients with unresectable primary liver cancer. MATERIALS AND
methodsBetween October 2015 and December 2016, 40 patients were enrolled and randomly allocated to either the IRE group (n = 22) or the IRE-NK group (n = 18). All adverse events experienced by the patients were recorded; the changes in tumor biomarkers [AFP, CA 19-9, circulating tumor cells (CTCs)], lymphocyte number and function, quality of life, clinical response, progression-free survival (PFS) and overall survival (OS) were assessed.
resultsPatients who received combination therapy exhibited significantly longer median PFS and OS than who just received IRE (PFS 15.1 vs. 10.6 months, P < 0.05, OS 17.9 vs. 23.2 months, P < 0.05). The combination therapy of IRE and NK cell immunotherapy significantly reduced CTCs and increased immune function and Karnofsky performance status.
conclusionOur data suggest a novel, promising combination therapy using IRE and allogenic NK cell immunotherapy. Larger clinical trials are required to confirm these conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.